<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890784</url>
  </required_header>
  <id_info>
    <org_study_id>DasaHIT</org_study_id>
    <nct_id>NCT02890784</nct_id>
  </id_info>
  <brief_title>Dasatinib Holiday for Improved Tolerability</brief_title>
  <acronym>DasaHIT</acronym>
  <official_title>Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Andreas Hochhaus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve
      disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase
      Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dasatinib is indicated in Europe for:

        -  Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+)
           chronic myeloid leukemia (CML) in the chronic phase

        -  Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy
           including imatinib

        -  Ph+ acute lymphoblastic leukemia (ALL) and lymphoid blast CML with resistance or
           intolerance to prior therapy Compared to imatinib, dasatinib in CML achieves faster and
           better responses. Dasatinib is known for its selected toxicities (fluid retention,
           edema, pleural effusion, and hematological toxicity) requiring dose reductions or
           treatment interruptions; these toxicities are more frequent in the first two years of
           treatment. A randomized dose optimization trial for QD dosing vs. BID dosing has
           demonstrated non-inferiority with regards to efficacy with an improved toxicity profile.
           In a pilot study, analyzing patients with dasatinib toxicity, a fixed dasatinib weekend
           holiday allowed safe toxicity management without impairing efficacy. Furthermore the
           alternated schedule was also able to improve response parameters in patients that had
           never achieved an acceptable response prior to the onset of dasatinib holiday dosing
           schedule. The biological rationale for a holiday dosing schedule is that dasatinib has
           shown an improved cell death of CML cells even after short exposure times; this improved
           cell death exceeds the killing rate observed with imatinib in vitro. In summary, the
           reported preclinical and clinical evidence indicates that efficacy seems to require
           adequate dasatinib Cmax, while low Cmin (five half-lives between doses) does not impair
           efficacy nor induces drug resistance. It is speculated that a weekend holiday, allowing
           a better tolerability, would improve patients' drug adherence. The Investigators
           hypothesize that a dasatinib holiday schedule (5x100mg+2x0mg weekly) compared to a
           regular dose (7x100mg weekly) will reduce the rate of clinically significant toxicity
           (e.g., fluid retention, hematological toxicity, musculoskeletal pain) by 20% observed
           within the first two years of treatment. The Investigators also hypothesize that the
           dasatinib holiday schedule is non-inferior to dasatinib regular dose in achieving the
           European LeukemiaNet (ELN) recommended levels of response within the first 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative toxicity score</measure>
    <time_frame>month 24</time_frame>
    <description>The cumulative toxicity score after two years of dasatinib treatment. More specifically, toxicity will be assessed taking into account both the rate of grade 2-4 toxicities and the cumulative severity of adverse events of specific interest. The following AEs of specific interest will be used to compose the cumulative toxicity score:
Pleural effusion
Fluid retention, other (edema, pericardial effusion, pulmonary arterial hypertension, congestive heart failure, pulmonary edema)
Hematological toxicity (neutropenia, thrombocytopenia, anemia)
Others (Musculoskeletal pain, skin toxicity (rash), gastrointestinal toxicity (nausea, diarrhea, abdominal pain, vomiting)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of molecular Response</measure>
    <time_frame>month 24</time_frame>
    <description>The co-primary endpoint of the study is: rate of major molecular response (MMR) as assessed by BCR-ABL (IS [International Score] in %) -monitoring by 24 months to safeguard non-inferiority of the test cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>month 24</time_frame>
    <description>Quality of life assessment via Patient-Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular Response</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Rate of molecular response (MMR)as assessed by BCR-ABL (IS [International Score] in %) at 6 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>A. Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib (SPRYCEL®)</intervention_name>
    <description>Treatment optimization for patients with chronic myeloid leukemia (CML)</description>
    <arm_group_label>A. Standard arm</arm_group_label>
    <arm_group_label>B. Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph+
             chromosome [t(9;22)(q34;q11)].

          -  Ph negative cases or patients with variant translocations who are BCR-ABL positive in
             multiplex PCR4 will be also considered eligible.

          -  ECOG performance status ≤2.

          -  Age ≥ 18 years old (no upper age limit is given)

          -  Serum levels of potassium, magnesium and total calcium within the normal limits (≥LLN
             [lower limit of normal] and ≤ULN [upper limit of normal]). Correction of electrolytes'
             levels with supplements to meet enrolment criteria is allowed.

          -  AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia

          -  Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia

          -  Total bilirubin ≤1.5 x ULN, except known Gilbert disease

          -  Serum creatinine ≤2 x ULN

          -  Written informed consent prior to any study procedures being performed.

        For 1st-line patients:

        • Pre-treatment with hydroxyurea up to 6 months and imatinib or dasatinib for duration of
        up to 4 weeks is permitted.

        For ≥ 2nd-line patients:

        • Patients with treatment failure according to the 2013 ELN Recommendations criteria3 or
        treatment intolerance as assessed by the investigator after prior treatment with TKIs other
        than dasatinib (imatinib, nilotinib, bosutinib, ponatinib).

        Exclusion Criteria:

          -  Previous allogeneic stem cell transplantation (AlloSCT)

          -  Known impaired cardiac function, including any of the following:

               -  Congenital long QT syndrome

               -  History of or presence of clinically significant ventricular or atrial
                  tachyarrhythmia

               -  QTc &gt;450 msec on screening ECG

               -  Myocardial infarction within 6 months prior to starting therapy

          -  Other clinical significant heart disease (e.g. unstable angina pectoris, congestive
             heart failure)

          -  Acute or chronic viral hepatitis with moderate or severe hepatic impairment
             (Child-Pugh scores &gt;6), even if controlled

          -  Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled
             infections, acute or chronic liver and renal disease) that could cause unacceptable
             safety risks or compromise compliance with the protocol

          -  Impaired gastrointestinal function or disease that may alter the absorption of study
             drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea,
             malabsorption syndrome, small bowel resection or gastric by-pass surgery)

          -  Concomitant medications known to be strong inducers or inhibitors of the CYP450
             isoenzyme CYP3A4

          -  Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who
             have not recovered from side effects of such therapy

          -  Patients who are pregnant or breastfeeding or women of reproductive potential not
             employing an effective method of birth control. Women of childbearing potential must
             have a negative serum pregnancy test within 14 days prior to administration of
             dasatinib. Post-menopausal women must be amenorrheic for at least 12 months in order
             to be considered of non-childbearing potential. Male and female patients must agree to
             employ an effective method of birth control throughout the study and for up to 3
             months following discontinuation of study drug

          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
             mandatory)

          -  Active autoimmune disorder, including autoimmune hepatitis

          -  Known serious hypersensitivity reactions to dasatinib

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention

          -  Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hochhaus, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jena University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christiane Clauss, M.Sc.</last_name>
    <phone>+49 3641 939 6661</phone>
    <email>dasahit@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Fabisch, Dr.</last_name>
    <phone>+49 3641 939 6670</phone>
    <email>dasahit@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>9621‐381 637</phone_ext>
      <email>weikersthal.ludwig@gesundheitszentrum.klinikum-amberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Klausmann</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Klausmann, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>6021‐342780</phone_ext>
      <email>mk@klausmann.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>228‐287 15229</phone_ext>
      <email>dominik.wolf@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hertenstein, Prof. Dr.</last_name>
      <email>bernd.hertenstein@klinikum-bremen-mitte.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, PD Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>371‐33343045</phone_ext>
      <email>m.haenel@skc.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Mohm/Prange-Krex</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Mohm, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>351‐4416018</phone_ext>
      <email>mohm@onkopraxis-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Ordemann, Prof. Dr.</last_name>
      <email>Rainer.Ordemann@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Göthert, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>201‐723 2553</phone_ext>
      <email>joachim.goethert@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabian Lang, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>69 6301 4013</phone_ext>
      <email>fabian.lang@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Karl‐Leisner Klinikum</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Runde, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>2823 891447</phone_ext>
      <email>volker.runde@wah.kkikk.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Gemeinschaftspraxis Halberstadt</name>
      <address>
        <city>Halberstadt</city>
        <zip>38820</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Maas, Dr. med.</last_name>
      <email>onko-praxis-hbs@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MediProjekt GbR</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Koenigsmann, Prof. Dr.</last_name>
      <email>koenigsmann@onkologie-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hochhaus, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>36419324201</phone_ext>
      <email>andreas.hochhaus@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Annamaria Brioli, PhD MD</last_name>
      <phone>+49</phone>
      <phone_ext>36419324576</phone_ext>
      <email>annamaria.brioli@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut für med. Dokumentation, Gutachtenstellung, Gesundheitsförderung und Qualitätssicherung GbR</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Hansen, Prof. Dr.</last_name>
      <email>richard.hansen@pfalz-onko.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarethe Schmier, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>721‐974 3050</phone_ext>
      <email>margarethe.schmier@klinikum-karlsruhe.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Repp, Prof. Dr.</last_name>
      <email>roland.repp@krankenhaus-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig‐Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn‐Niklas Heydrich, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>431‐16971297</phone_ext>
      <email>bjoern.heydrich@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>341‐9713131</phone_ext>
      <email>dietger.niederwieser@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Saußele, PD Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>621‐383‐6966</phone_ext>
      <email>susanne.saussele@medma.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>7171‐701‐1302</phone_ext>
      <email>holger.hebart@stauferklinikum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie/ Onkologie</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Zingerle, Dr. med.</last_name>
      <email>schmidt@onkologie-pasing.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Schmidt, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>251‐ 8349963</phone_ext>
      <email>Eva.Schmidt2@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Südhoff, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>854‐5300 2356</phone_ext>
      <email>thomas.suedhoff@klinikum-passau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Reutlingen GmbH</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Wacker, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>7121‐2003988</phone_ext>
      <email>wacker_a@klin-rt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Junghanß, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>381‐4947421</phone_ext>
      <email>christian.junghanss@med.uni-rostock.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Südstadt Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Krammer‐Steiner, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>381‐4401 6100</phone_ext>
      <email>beate.steiner@kliniksued-rostock.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, Dr. med.</last_name>
      <phone>+49</phone>
      <phone_ext>651‐947‐2571</phone_ext>
      <email>mahlberg@mutterhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Stegelmann, Dr. med.</last_name>
      <email>Frank.Stegelmann@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul La Rosée, Prof. Dr.</last_name>
      <email>paul.larosee@sbk-vs.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Andreas Hochhaus</investigator_full_name>
    <investigator_title>Director of the Clinic of Internal Medicine II</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

